Ruthigen starts patient enrolment in Phase I/II trial of RUT58-60
A total of 150 patients will be enrolled in the randomized, double-blind trial, which is designed to evaluate RUT58-60’s safety, tolerability and potential efficacy for use as an
Pacira BioSciences has entered into an exclusive agreement with Italian pharmaceutical company Molteni Farmaceutici to distribute and commercialise Exparel across the EU and the UK.
Under the agreement, MDD has the rights to market, sell and distribute Imprimis’ patent-pending Go Dropless™ formulations and other ophthalmic formulations in Puerto Rico. In addition, the agreement
K-Ras is the most commonly mutated oncogene in human cancers, with about 30% of all cancers harbouring activating ras mutations. Furthermore, cancers with a high prevalence of K-Ras